$15.21
SWK Holdings


Performance
Dividends
1W
1M
YTD
1Y
3Y
15/36
Growth
Score
5/36
Dividend
Score
Valuation
PE Ratio
10.18
PS Ratio
4.56
RSI
-
0
PEG Ratio
-0.05
3
PRG Ratio
0.15
PDG Ratio
0
Growth
2023
2024
2025*
2026*
3
Revenue
Revenue
*Analyst estimated growth
Fundamentals
3
Rule
of 40
86.04%
3
Gross Margin
79.87%
3
Current Ratio
11.3
Return on Assets
5.52%
Return on Equity
6.37%
Return on inv. Capital
4.5%
Dividend Growth
2023
2024
2025*
2
*Estimated growth
Dividends
Yield
26.3%
Per Year
1x
Payout Ratio
0%
Institutional Holder
Shares
Holders
Financials
Yealy
Quarterly
Revenue 2024 44.99M
2018
2019
2020
2021
2022
2023
2024
6
Net Income 2024 13.49M
2018
2019
2020
2021
2022
2023
2024
6
Gross Profit 2024 42.78M
2018
2019
2020
2021
2022
2023
2024
6
Events

SWKH
SWK Holdings
in 284 days
[missing "en-US.common.--" translation]
Earnings per Share is expected with - and revenue with - .

SWKH
SWK Holdings
in 227 days
[missing "en-US.common.--" translation]
Earnings per Share is expected with - and revenue with - .

SWKH
SWK Holdings
in 102 days
[missing "en-US.common.--" translation]
Earnings per Share is expected with - and revenue with - .
About
Sector/Industry
Financial Services
Asset Management
IPO Date
23.09.1999
MaketCap
186.62M
Country
US
CEO
Jody. D Staggs
Description
SWK Holdings Corporation, a specialty finance company that focuses on the healthcare sector. It operates in two segments, Finance Receivables and Pharmaceutical Development. The company provides customized financing solutions to a range of life science companies, including companies in the biotechnology, medical device, medical diagnostics and related tools, animal health, and pharmaceutical industries, as well as institutions and inventors. It also offers non-discretionary investment advisory services to institutional clients in separately managed accounts to invest in life science finance. In addition, the company engages in the pharmaceutical development, formulation and manufacturing, and licensing business through the Peptelligence platform. Further, it intends to out-license its internal product pipeline to create novel formulations using its proprietary technology to develop treatments for patients and caregivers. The company was formerly known as Kana Software, Inc. and changed its name to SWK Holdings Corporation in December 2009. SWK Holdings Corporation was founded in 1996 and is headquartered in Dallas, Texas.
Updated 21.07.2025